Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BNXTFNASDAQ:INGNNASDAQ:PRQRNYSEAMERICAN:STXS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNXTFBioNxt Solutions$0.38$0.34$0.11▼$0.43$43.99M0.69,071 shsN/AINGNInogen$6.62+1.4%$6.85$5.70▼$13.33$177.99M1.63239,904 shs165,052 shsPRQRProQR Therapeutics$1.70+1.8%$1.46$1.07▼$4.62$178.86M0.35630,330 shs255,138 shsSTXSStereotaxis$2.13+2.9%$1.91$1.54▼$2.72$180.48M1.54362,988 shs193,167 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNXTFBioNxt Solutions0.00%-0.24%+11.76%+5.56%+39.94%INGNInogen0.00%+6.53%-10.30%-31.41%-25.88%PRQRProQR Therapeutics0.00%-2.34%+16.78%-28.63%-11.17%STXSStereotaxis0.00%-0.96%+5.08%-4.61%+4.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNXTFBioNxt SolutionsN/AN/AN/AN/AN/AN/AN/AN/AINGNInogen3.89 of 5 stars3.03.00.03.92.11.71.3PRQRProQR Therapeutics3.3563 of 5 stars4.65.00.00.03.40.00.0STXSStereotaxis0.587 of 5 stars0.02.00.00.00.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNXTFBioNxt Solutions 0.00N/AN/AN/AINGNInogen 2.00Hold$9.5043.50% UpsidePRQRProQR Therapeutics 3.13Buy$8.00370.59% UpsideSTXSStereotaxis 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BNXTF, PRQR, INGN, and STXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025INGNInogenNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Moderate Buy$12.005/13/2025PRQRProQR TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $9.005/8/2025INGNInogenStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$10.00 ➝ $7.004/29/2025PRQRProQR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$8.004/29/2025PRQRProQR TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.004/9/2025INGNInogenNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/14/2025PRQRProQR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $12.003/14/2025PRQRProQR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/10/2025PRQRProQR TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNXTFBioNxt Solutions$280K157.11N/AN/A($0.04) per share-9.50INGNInogen$339.96M0.52N/AN/A$8.79 per share0.75PRQRProQR Therapeutics$18.97M9.43N/AN/A$0.55 per share3.09STXSStereotaxis$26.77M6.74N/AN/A$0.20 per share10.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNXTFBioNxt Solutions-$5.72M-$0.04N/A∞N/A-15,638.71%N/A-683.78%N/AINGNInogen-$102.45M-$1.15N/AN/AN/A-15.89%-27.38%-16.77%8/5/2025 (Estimated)PRQRProQR Therapeutics-$30.43M-$0.35N/AN/AN/A-134.31%-71.58%-19.70%8/14/2025 (Estimated)STXSStereotaxis-$20.71M-$0.28N/AN/AN/A-85.79%-162.54%-51.26%8/11/2025 (Estimated)Latest BNXTF, PRQR, INGN, and STXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025PRQRProQR Therapeutics-$0.09-$0.1082-$0.0182-$0.11$4.90 million$4.89 million5/7/2025Q1 2025INGNInogen-$0.52-$0.25+$0.27-$0.25$79.57 million$82.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNXTFBioNxt SolutionsN/AN/AN/AN/AN/AINGNInogenN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ASTXSStereotaxisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNXTFBioNxt SolutionsN/A0.040.04INGNInogenN/A2.662.34PRQRProQR TherapeuticsN/A2.332.33STXSStereotaxisN/A1.390.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNXTFBioNxt SolutionsN/AINGNInogen89.94%PRQRProQR Therapeutics32.65%STXSStereotaxis45.35%Insider OwnershipCompanyInsider OwnershipBNXTFBioNxt SolutionsN/AINGNInogen1.46%PRQRProQR Therapeutics8.40%STXSStereotaxis18.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNXTFBioNxt Solutions20115.76 millionN/ANot OptionableINGNInogen1,03026.89 million23.58 millionOptionablePRQRProQR Therapeutics180105.21 million74.82 millionOptionableSTXSStereotaxis13084.73 million69.04 millionNot OptionableBNXTF, PRQR, INGN, and STXS HeadlinesRecent News About These CompaniesStereotaxis shareholders approve board nominees and auditorMay 21, 2025 | investing.comEarnings call transcript: Stereotaxis Q1 2025 reports stable EPS, revenue growthMay 14, 2025 | uk.investing.comStereotaxis, Inc. (AMEX:STXS) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comLagoda Investment Management L.P. Purchases 295,700 Shares of Stereotaxis, Inc. (NYSEAMERICAN:STXS)May 14, 2025 | marketbeat.comStereotaxis, Inc.: Stereotaxis Reports 2025 First Quarter Financial ResultsMay 14, 2025 | finanznachrichten.deStereotaxis Inc (STXS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...May 14, 2025 | finance.yahoo.comStereotaxis reiterates double-digit revenue growth outlook for 2025 as recurring revenue and MAGiC adoption rampMay 13, 2025 | msn.comStereotaxis, Inc. (STXS) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comStereotaxis Inc. (STXS) Reports Q1 Loss, Tops Revenue EstimatesMay 12, 2025 | zacks.comStereotaxis Reports 2025 First Quarter Financial ResultsMay 12, 2025 | globenewswire.comStereotaxis Inc (STXS) Q1 2025: Everything You Need to Know Ahead of EarningsMay 10, 2025 | finance.yahoo.comStereotaxis (STXS) to Release Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comStereotaxis to Showcase GenesisX Robotic System at Heart Rhythm Symposium 2025April 23, 2025 | nasdaq.comStereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025April 22, 2025 | globenewswire.comStereotaxis to feature first-ever live demo of GenesisX Robotic SystemApril 21, 2025 | markets.businessinsider.comStereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025April 21, 2025 | globenewswire.comStereotaxis management to meet virtually with Lake StreetApril 1, 2025 | markets.businessinsider.com3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025March 26, 2025 | zacks.comNvidia’s Support Boosts Stereotaxis (STXS) in Advancing Robotic SurgeryMarch 24, 2025 | msn.comStereotaxis gains support from NVIDIA for AI roboticsMarch 21, 2025 | uk.investing.comStereotaxis Jumps 15% on NVIDIA's AI-Driven Collaboration: Is It a Buy Now?March 21, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBNXTF, PRQR, INGN, and STXS Company DescriptionsBioNxt Solutions OTCMKTS:BNXTF$0.38 0.00 (0.00%) As of 05/23/2025BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.Inogen NASDAQ:INGN$6.62 +0.09 (+1.38%) Closing price 04:00 PM EasternExtended Trading$6.62 0.00 (0.00%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.ProQR Therapeutics NASDAQ:PRQR$1.70 +0.03 (+1.80%) Closing price 04:00 PM EasternExtended Trading$1.70 0.00 (-0.29%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.Stereotaxis NYSEAMERICAN:STXS$2.13 +0.06 (+2.90%) Closing price 04:10 PM EasternExtended Trading$2.12 0.00 (-0.23%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
